Gene therapy can cure lameness in horses, research finds

   
   
Lame horse
18 Oct 2017 13:41:56.233

PA 243/17

Injecting DNA into injured horse tendons and ligaments can cure lameness, new research involving scientists at Kazan Federal University, Moscow State Academy and The University of Nottingham has found.

The gene therapy technology was used in horses that had gone lame due to injury and within two to three weeks the horses were able to walk and trot. Within just two months they were back to full health, galloping and competing.

The study has big implications not just for the veterinary world but the future of human medicine – injuries like these are common in people as well as animals, not just in lameness but in other illnesses and diseases from the legs and arms through to the back and hips.

Click here for full story

The new findings are the result of a partnership between the Kazan Federal University and Moscow State Academy of Veterinary Medicine and Biotechnology and Nottingham’s School of Veterinary Medicine and Science.

Dr Catrin Rutland, Assistant Professor of Anatomy and Developmental Genetics, led the work at Nottingham.

She said: “This pioneering study advances not only equine medicine but has real implications for how other species and humans are treated for lameness and other disorders in the future. The horses returned to full health after their injuries and did not have any adverse side effects. This is a very exciting medical innovation.”

The ground-breaking, international study, published in the academic journal Frontiers in Veterinary Science, demonstrated gene therapy using a combination of the Vascular Endothelial Growth Factor gene VEGF164, to enhance the growth of blood vessels and bone morphogenetic protein 2 (BMP2), which plays an important role in the development of bone and cartilage.

Faster healing

Both the genes were derived from horses, resulting in the biosynthesis of natural horse proteins in the treated animals. They were cloned into a single plasmid DNA, which is both biologically safe and unlikely to provoke an immune reaction from the body.

Current medical therapies have a relapse rate of 60 per cent and even the best regenerative medicine treatments have a 20 per cent relapse rate and take five to six months to work.

The new therapy is therefore very promising as it offers a much faster healing time and could significantly reduce relapse rates.

The results also showed that the tissue within the horses limbs has also fully recovered and 12 months after the revolutionary treatment the horses were completely fit, active and pain free.

Many medicines and treatments have adverse effects, but no side effects or bad reactions were seen in the horses treated.

Professor Albert Rizvanov, who led the study and is based at Kazan Federal University, said: “Advancing medicine, relieving pain and restoring function were the main aims of this study. We have shown that these are possible and within a much shorter time span than treatments available at the moment. In addition, we could use this type of therapy in other injuries and in many other situations ranging from fertility problems through to spinal cord injuries.

“Our next step is to secure more funding for an even larger trial to help more animals and improve and treat other disorders in the hope that one day we can routinely use this treatment around the world.”

The research was funded through a Program of Competitive Growth at Kazan Federal University.

The research paper, Gene Therapy Using Plasmid DNA Encoding Vascular Endothelial Growth Factor 164 and Fibroblast Growth Factor 2 Genes for the Treatment of Horse Tendinitis and Desmitis: Case Reports, is available online at Frontiers in Veterinary Science.

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: 

The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named University of the Year for Graduate Employment in the 2017 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017 and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer and industry partner - locally and globally.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…

 

Story credits

More information is available from Dr Catrin Rutland in the School of Veterinary Medicine and Science, University of Nottingham on +44 (0)115 951 6573, catrin.rutland@nottingham.ac.uk

Emma Thorne Emma Thorne - Media Relations Manager

Email: emma.thorne@nottingham.ac.uk Phone: +44 (0)115 951 5793 Location: University Park

Additional resources

No additional resources for this article

Related articles

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk